Epigenetic alteration of the metallothionein 1e gene in human endometrial carcinomas

Tumor Biology

Volumn 30, Issue 2, 2009, Pages 93-99

  Tse, Ka Yu ^a   Liu, Vincent Wing Sun ^a   Chan, David Wai ^a   Chiu, Pui Man ^a   Tam, Kar Fai ^a   Chan, Karen Kar Loen ^a   Liao, Xiao Yun ^a   Cheung, Annie Nga Yin ^a   Ngan, Hextan Yuen Sheung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Endometrial carcinoma; Metallothionein 1E gene; Promoter hypermethylation

Indexed keywords

AZACITIDINE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HHA1 ENZYME; HHA2 ENZYME; MESSENGER RNA; METALLOTHIONEIN 1E; METALLOTHIONEIN I; RESTRICTION ENDONUCLEASE; UNCLASSIFIED DRUG; METALLOTHIONEIN; METALLOTHIONEIN 1E PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER CELL; CONTROLLED STUDY; DNA METHYLATION; ENDOMETRIUM CARCINOMA; ENDOMETRIUM CELL; ENDOMETRIUM HYPERPLASIA; EPIGENETICS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; OVARY CELL; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERINE CERVIX; ENDOMETRIUM TUMOR; GENETIC EPIGENESIS; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; TUMOR CELL LINE;

BASE SEQUENCE; CELL LINE, TUMOR; DNA METHYLATION; ENDOMETRIAL NEOPLASMS; EPIGENESIS, GENETIC; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; METALLOTHIONEIN; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC;

EID: 65449153636     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218032     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
2. Pecorelli S: FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006; 95: 105 -143.
3. Hecht JL, Mutter GL: Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006;24:4783 - 4791.
4. Shang Y: Molecular mechanisms of oestrogen and SERMs in endometrial carcinogen-esis. Nat Rev Cancer 2006;6:360-368.
5. Zhou XC, Dowdy SC, Podratz KC, Jiang SW: Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment. Gynecol Oncol 20 07; 107: 143 - 153.
6. Cherian MG, Jayasurya A, Bay BH: Metallo-thioneins in human tumors and potential roles in carcinogenesis. Mutat Res 2003; 533: 201-209.
7. Theocharis SE, Margeli AP, Klijanienko JT, Kouraklis GP: Metallothionein expression in human neoplasia. Histopathology 2004; 45:103-118.
8. Shukla VK, Aryya NC, Pitale A, Pandey M, Dixit VK, Reddy CD, Gautam A: Metallo-thionein expression in carcinoma of the gallbladder. Histopathology 1998; 33: 154 -157.
9. Surowiak P, Materna V, Kaplenko I, Spaczyński M, Dietel M, Lage H, Zabel M: Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Arch 2005; 447:626-633.
10. Poulsen CB, Borup R, Borregaard N, Nielsen FC, Moller MB, Ralfkiaer E: Prognostic significance of metallothionein in B-cell lym-phomas. Blood 2006; 108:3514-3519.
11. Bay BH, Jin R, Huang J, Tan PH: Metallo-thionein as a prognostic biomarker in breast cancer. Exp Biol Med 2006; 231:1516-1521.
12. Datta J, Majumder S, Kutay H, Motiwala T, Frankel W, Costa R, Cha HC, MacDougald OA, Jacob ST, Ghoshal K: Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinosi-tol 3-kinase signaling cascade. Cancer Res 2007; 67:2736-2746.
13. Weinlich G, Zelger B: Metallothionein over-expression, a highly significant prognostic factor in thin melanoma. Histopathology 2007; 51: 280-283.
14. Ferrario C, Lavagni P, Gariboldi M, Miranda C, Losa M, Cleris L, Formelli F, Pilotti S, Pierotti MA, Greco A: Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma. Lab Invest 2008; 88: 474 -481.
15. Wei H, Desouki M, Lin S, Xiao D, Franklin R, Feng P: Differential expression of metallo-thioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues. Mol Cancer 2008; 7: 7.
16. Surowiak P, Materna V, Maciejczyk A, Pudełko M, Markwitz E, Spaczyńsk i M, Die-tel M, Zabel M, Lage H: Nuclear metallothio-nein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome. Virchows Arch 2007; 450: 279-285.
17. McCluggage WG, Maxwell P, Hamilton PW, Jasani B: High metallothionein expression is associated with features predictive of aggressive behaviour in endometrial carcinoma. Histopathology 1999; 34:51-55.
18. Ioachim EE, Kitsiou E, Carassavoglou C, Stefanaki S, Agnantis NJ: Immunohisto-chemical localization of metallothionein in endometrial lesions. J Pathol 2000; 191:269-73.
19. Liu Y, Lee KF, Ng EHY, Yeung WSB, Ho PC: Gene expression profiling of human peri-implantation endometria between natural and stimulated cycles. Fertil Steril 2008; 90: 2152-2164.
20. Kvasha S, Gordiyuk V, Kondratov A, Ugryn D, Zgonnyk YM, Rynditch AV, Vozianov AF: Hypermethylation of the 5′CpG island of the FHIT gene in clear cell renal carcinomas. Cancer Lett 2008; 265:250-257.
21. Nagasaka T, Goel A, Notohara K, Takahata T, Sasamoto H, Uchida T, Nishida N, Tanaka N, Boland CR, Matsubara N: Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis. Int J Cancer 2008; 122: 2429-2436.
22. Morahan JM, Yu B, Trent RJ, Pamphlett R: Are metallothionein genes silenced in ALS? Toxicol Lett 2007; 168:83-87.
23. Jin R: Metallothionein 1E mRNA is highly expressed in oestrogen receptor-negative human invasive ductal breast cancer. Br J Cancer 2000; 83: 319-323.
24. Nguyen A, Jing Z, Mahoney PS, Davis R, Sik-ka SC, Agrawal KC, Abdel-Mageed AB: In vivo gene expression profile analysis of metallothionein in renal cell carcinoma. Cancer Lett 2000; 160:133-140.